Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 100

1.

Antiangiogenic tetrathiomolybdate enhances the efficacy of doxorubicin against breast carcinoma.

Pan Q, Bao LW, Kleer CG, Brewer GJ, Merajver SD.

Mol Cancer Ther. 2003 Jul;2(7):617-22.

2.
3.

Oral silibinin inhibits lung tumor growth in athymic nude mice and forms a novel chemocombination with doxorubicin targeting nuclear factor kappaB-mediated inducible chemoresistance.

Singh RP, Mallikarjuna GU, Sharma G, Dhanalakshmi S, Tyagi AK, Chan DC, Agarwal C, Agarwal R.

Clin Cancer Res. 2004 Dec 15;10(24):8641-7.

4.

Inactivation of NF-kappaB by 3,3'-diindolylmethane contributes to increased apoptosis induced by chemotherapeutic agent in breast cancer cells.

Rahman KM, Ali S, Aboukameel A, Sarkar SH, Wang Z, Philip PA, Sakr WA, Raz A.

Mol Cancer Ther. 2007 Oct;6(10):2757-65. Epub 2007 Oct 3.

5.
6.

Copper deficiency induced by tetrathiomolybdate suppresses tumor growth and angiogenesis.

Pan Q, Kleer CG, van Golen KL, Irani J, Bottema KM, Bias C, De Carvalho M, Mesri EA, Robins DM, Dick RD, Brewer GJ, Merajver SD.

Cancer Res. 2002 Sep 1;62(17):4854-9.

7.

Targeting of nuclear factor kappaB Pathways by dehydroxymethylepoxyquinomicin, a novel inhibitor of breast carcinomas: antitumor and antiangiogenic potential in vivo.

Matsumoto G, Namekawa J, Muta M, Nakamura T, Bando H, Tohyama K, Toi M, Umezawa K.

Clin Cancer Res. 2005 Feb 1;11(3):1287-93.

8.

Antitumor effects of doxorubicin followed by zoledronic acid in a mouse model of breast cancer.

Ottewell PD, Mönkkönen H, Jones M, Lefley DV, Coleman RE, Holen I.

J Natl Cancer Inst. 2008 Aug 20;100(16):1167-78. doi: 10.1093/jnci/djn240. Epub 2008 Aug 11.

9.

The role of copper suppression as an antiangiogenic strategy in head and neck squamous cell carcinoma.

Cox C, Teknos TN, Barrios M, Brewer GJ, Dick RD, Merajver SD.

Laryngoscope. 2001 Apr;111(4 Pt 1):696-701.

PMID:
11359142
11.

REIC/Dkk-3 overexpression downregulates P-glycoprotein in multidrug-resistant MCF7/ADR cells and induces apoptosis in breast cancer.

Kawasaki K, Watanabe M, Sakaguchi M, Ogasawara Y, Ochiai K, Nasu Y, Doihara H, Kashiwakura Y, Huh NH, Kumon H, Date H.

Cancer Gene Ther. 2009 Jan;16(1):65-72. doi: 10.1038/cgt.2008.58. Epub 2008 Jul 25.

PMID:
18654608
12.

Suppression of tumor recurrence and metastasis by a combination of the PHSCN sequence and the antiangiogenic compound tetrathiomolybdate in prostate carcinoma.

van Golen KL, Bao L, Brewer GJ, Pienta KJ, Kamradt JM, Livant DL, Merajver SD.

Neoplasia. 2002 Sep-Oct;4(5):373-9.

13.

Copper lowering therapy with tetrathiomolybdate as an antiangiogenic strategy in cancer.

Brewer GJ.

Curr Cancer Drug Targets. 2005 May;5(3):195-202. Review.

PMID:
15892619
14.

Celecoxib enhances doxorubicin-induced cytotoxicity in MDA-MB231 cells by NF-kappaB-mediated increase of intracellular doxorubicin accumulation.

van Wijngaarden J, van Beek E, van Rossum G, van der Bent C, Hoekman K, van der Pluijm G, van der Pol MA, Broxterman HJ, van Hinsbergh VW, Löwik CW.

Eur J Cancer. 2007 Jan;43(2):433-42. Epub 2006 Nov 9.

PMID:
17097285
15.

The nuclear transcription factor kappaB/bcl-2 pathway correlates with pathologic complete response to doxorubicin-based neoadjuvant chemotherapy in human breast cancer.

Buchholz TA, Garg AK, Chakravarti N, Aggarwal BB, Esteva FJ, Kuerer HM, Singletary SE, Hortobagyi GN, Pusztai L, Cristofanilli M, Sahin AA.

Clin Cancer Res. 2005 Dec 1;11(23):8398-402.

16.

Tetrathiomolybdate protects against cardiac damage by doxorubicin in mice.

Hou G, Dick R, Abrams GD, Brewer GJ.

J Lab Clin Med. 2005 Nov;146(5):299-303.

PMID:
16242529
17.
18.

Cisplatin-induced antitumor activity is potentiated by the soy isoflavone genistein in BxPC-3 pancreatic tumor xenografts.

Mohammad RM, Banerjee S, Li Y, Aboukameel A, Kucuk O, Sarkar FH.

Cancer. 2006 Mar 15;106(6):1260-8.

19.

Downregulation of NF-kappaB activation in a H4IIE transfectant insensitive to doxorubicin-induced apoptosis.

Chovolou Y, Wätjen W, Kampkötter A, Kahl R.

Toxicology. 2007 Mar 22;232(1-2):89-98. Epub 2006 Dec 17.

PMID:
17223244
20.

Suberoylanilide hydroxamic acid (Zolinza/vorinostat) sensitizes TRAIL-resistant breast cancer cells orthotopically implanted in BALB/c nude mice.

Shankar S, Davis R, Singh KP, Kurzrock R, Ross DD, Srivastava RK.

Mol Cancer Ther. 2009 Jun;8(6):1596-605. doi: 10.1158/1535-7163.MCT-08-1004. Epub 2009 Jun 9.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk